Skip to main content
Premium Trial:

Request an Annual Quote

Korean MFDS Clears Gencurix Lung Cancer Test

NEW YORK (GenomeWeb) – The Korean Ministry of Food and Drug Safety has cleared Gencurix's GenesWell ddEGFR Mutation Test for clinical use as a companion diagnostic, the company said this week.

Gencurix's assay can be used to select which non-small cell lung cancer patients will respond to tyrosine kinase inhibitors. The test is run on Bio-Rad's droplet digital PCR-based platform.

CEO Sang Rae Cho said in a statement that the clearance is in line with the Seoul-based company's strategy to deliver companion diagnostics to the clinical market. "We are ... trying to provide more accurate, targeted therapy by researching and developing [companion diagnostics] in various cancer fields," he said.

Gencurix's test is capable of detecting 46 mutations in the EGFR gene associated with response to therapies that inhibit tyrosine kinase. The panel includes the T790M mutation and C797S mutations, associated with second- and third-generation drug responses, respectively.

To meet Korean MFDS guidelines for clearance, the company carried out a clinical trial in NSCLC patients, identifying patients who responded to Tarveca, a TKI marketed in Korea by Roche. Gencurix said it gained clearance on the basis of this validation.

The company is now preparing to seek a CE-IVD mark for the assay. It also is planning a clinical trial in the US ahead of a planned 2018 submission to the US Food and Drug Administration. It also said it intends to make the test available in the Chinese and Japanese markets.

Gencurix is separately planning to file its GenesWell BCT breast cancer prognostic with the agency for 510(k) clearance next year. The real-time PCR-based assay measures RNA biomarkers to predict patient survival rates in relation to chemotherapy.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.